Celsion Profit Margin 2006-2021 | CLSN

Current and historical gross margin, operating margin and net profit margin for Celsion (CLSN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Celsion net profit margin as of September 30, 2021 is -3912.2%.
Celsion Annual Profit Margins
Celsion Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.066B $0.001B
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.098B 7.97
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.439B 21.07
Biohaven Pharmaceutical Holding (BHVN) United States $7.569B 0.00
Arcus Biosciences (RCUS) United States $3.404B 0.00
Emergent Biosolutions (EBS) United States $2.322B 8.35
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.560B 0.00
Zymeworks (ZYME) Canada $0.915B 0.00
Ambrx Biopharma (AMAM) United States $0.390B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90